Further characterization of the role that ERG plays in PTEN-intact prostate cancers and/or in hormone-sensitive prostate cancers may reveal their interwoven molecular dependencies and the molecular mechanisms driving disease progression potentially leading to new treatment stratification schemes. The gene discussed is ERG; the disease is prostate cancer.